Second-Line Irinotecan/Cetuximab/Ramucirumab Combo Ups PFS in Advanced CRC

John SchieszerJun 6, 2018A combination of irinotecan, cetuximab, and ramucirumab may boost PFS in advanced CRC, when given after failure of oxaliplatin-and-bevacizumab –based therapy.

Source: CancerNetwork - June 7, 2018 Category: Cancer & Oncology Authors: A Source Type: news